Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Sponsor: University Hospital, Tours
Summary
Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"
Official title: Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2008-10
Completion Date
2013-10
Last Updated
2026-06-12
Healthy Volunteers
No
Interventions
MabThera
MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
Physiological serum : sodium chloride, sodium citrate
Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
Locations (30)
Hospital Henri Mondor
Paris, Créteil, France
Hospital
Grenoble, La Tronche, France
Hospital Bicêtre
Paris, Le Kremlin Bicêtre, France
Hospital Lyon Sud
Lyon, Pierre-Benite, France
Hospital Nord
Saint-Etienne, Saint Priez-en-Jarez, France
Hospital Sud
Amiens, France
Hospital
Angers, France
Hospital Saint-Jacques
Besançon, France
Hospital Pellegrin
Bordeaux, France
Hospital
Brest, France
Hospital
Caen, France
Hospital Gabriel Montpied
Clermont-Ferrand, France
Hospital Bocage
Dijon, France
Hospital Calmette
Lille, France
Hospital Dupuytren
Limoges, France
Hospital Edouard Herriot
Lyon, France
Hospital Conception
Marseille, France
Hospital Lapeyronie
Montpellier, France
Hospital Hôtel Dieu
Nantes, France
Hospital Pasteur
Nice, France
Hospital Saint Louis
Paris, France
Hospital Tenon
Paris, France
Hospital Pitié-Salpêtrière
Paris, France
Hospital Necker
Paris, France
Hospital Milétrie Jean Bernard
Poitiers, France
Hospital Maison Blanche
Reims, France
Hospital
Rennes, France
Hospital Bois-Guillaume
Rouen, France
Hospital Civil
Strasbourg, France
Hospital Bretonneau
Tours, France